W
WLC
Fitt Insider

Sequel Brands + Lifeforce Launch Ultimate Longevity Center: The 'Gym-as-Clinic' Goes Franchise

A new franchise concept of 'longevity studios' blends recovery therapies (red light, HBOT, cold plunge) with clinical upsells (biomarkers, NAD, GLP-1, HRT, peptides, IV).

clinics franchises biohacking healthspan

A clear signal that longevity is going mainstream isn’t a new paper: it’s when the format becomes a franchise.

Source: Fitt Insider

Fitt Insider reports the launch of Ultimate Longevity Center, a concept driven by Sequel Brands (Anthony Geisler; ex Xponential Fitness) in collaboration with biohacker Gary Brecka and the longevity medicine platform Lifeforce (co-founded by Tony Robbins).

What is Ultimate Longevity Center (per the piece)

The concept is presented as a “studio-as-clinic” with two tiers:

  • Base: guided recovery/optimization therapies

    • red light therapy
    • hyperbaric chamber sessions (HBOT)
    • cold plunges
    • hydrogen baths

  • Concierge / upgrade: clinical and pharmacological layer

    • precision biomarkers
    • NAD
    • GLP-1
    • HRT
    • peptides
    • IV therapies

In short: the “longevity studio” as the entry point, and the “longevity clinic” as the high-ticket monetization.

The Xponential playbook and its clinical application

Geisler is no newcomer to the wellness franchise model. With Xponential Fitness, he scaled brands like Club Pilates, StretchLab, CycleBar, and YogaSix — accumulating over 2,800 operational locations before his departure. The playbook was always the same: standardize the experience, lower the barrier to entry for franchisees, and scale fast with third-party capital.

Applying that logic to clinical services is, simultaneously, the biggest opportunity and the most serious risk in the sector. In a pilates studio, variability between locations affects client satisfaction. In a clinic prescribing GLP-1, HRT, or peptides, variability can affect patient safety. The distance between a “wellness franchise” and a “clinical franchise” is not just semantic: it involves state-by-state medical licenses, prescription oversight, cold chain for biological compounds, and pharmacovigilance protocols.

The regulatory risk isn’t theoretical either. The FTC has already acted against health franchises over unsubstantiated claims, and the FDA has intensified actions against compounding pharmacies supplying peptides and injectable compounds. A franchisee operating under a national brand inherits the legal exposure of the entire network: one incident at a single location can trigger scrutiny of the whole model.

How it compares to existing models

The market already has reference points for evaluating this move. Fountain Life (founded by Peter Diamandis and Tony Robbins) operates with a premium membership model (~$19,500/year) centered on advanced diagnostics and prevention. Human Longevity Inc. (founded by Craig Venter) combines genomic sequencing with imaging. Both have opted for controlled growth with owned locations, not franchises.

The difference with Ultimate Longevity Center is fundamental: the franchise model prioritizes distribution speed over clinical control. That doesn’t invalidate it, but it shifts quality responsibility to the individual franchisee — and to a regulatory framework that is still being defined.

Why this matters: the operating model

This type of move typically foreshadows the market’s future:

  1. Packaged standard

    • the product stops being “a unique clinic” and becomes “a replicable playbook.”

  2. Clinical upsell

    • the risk is that protocols get driven by margin rather than indication.

  3. Competition for distribution

    • the channel is no longer just the physician; it’s the wellness retail space (studios, gyms, memberships).

The tension: defensible prevention vs. ‘infinite menu’

The problem isn’t offering many things. It’s failing to properly separate:

  • solid prevention (habits, cardiometabolic, strength, sleep)
  • recovery (contrast protocols, HBOT where appropriate)
  • pharmacology/biologics (GLP-1, HRT, peptides) with strict criteria

If the sector doesn’t make that separation, two things follow: bad press and regulation. Publications like The Atlantic are already flagging the risks of the “longevity for everyone” model. The challenge for Ultimate Longevity Center will be proving that scaling fast doesn’t mean lowering the standard.

Primary source: Fitt Insider (Source: Fitt Insider, 2025).